Roche says wins priority review for Avastin in cervical cancer
ZURICH, July 15
ZURICH, July 15 (Reuters) - Roche said U.S. health regulators have granted a priority review of its Avastin when combined with chemotherapy to treat women with cervical cancer.
An approval by the U.S. Food and Drug Administration for treating advanced cervical cancer would open another large market for the medicine in patients for whom chemotherapy has been largely ineffective. About 4,000 women in the United States and 250,000 worldwide die each year from the disease.
"This regulatory application for Avastin is important because chemotherapy is the only approved treatment for women with metastatic, recurrent or persistent cervical cancer," Sandra Horning, Roche's chief medical officer and head of Global Product Development, said in a statement. (Reporting By Katharina Bart; Editing by Michael Urquhart)